FDA-APPROVED DOSE AND SCHEDULE

Metastatic
Pancreatic Cancer (mPC)
Metastatic Pancreatic Cancer (mPC)
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for metastatic pancreatic cancer (MPAC) 125 mg/m2 bottle and gemcitabine 1000 mg/m2 bottle - icon
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for metastatic pancreatic cancer (MPAC) 125 mg/m2 bottle and gemcitabine 1000 mg/m2 bottle - icon

ILLUSTRATIVE PURPOSES ONLY

  • Administer ABRAXANE
    followed by gemcitabine weekly
    for 3 weeks, then 1 week break
    of each 28-day cycle
  • ABRAXANE is administered intravenously over 30-40 minutes
  • ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine
  • Administer ABRAXANE followed by gemcitabine weekly for 3 weeks, then 1 week break of each 28-day cycle
  • ABRAXANE is administered intravenously over 30-40 minutes
  • ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine
Metastatic
Breast Cancer (MBC)
Metastatic Breast Cancer (MBC)
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for metastatic breast cancer (MBC) 260 mg/m2 bottle - icon
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for metastatic breast cancer (MBC) 260 mg/m2 bottle - icon

ILLUSTRATIVE PURPOSES ONLY

  • Administer ABRAXANE once every 3 weeks
  • ABRAXANE is administered intravenously over 30 minutes
  • ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
Advanced Non–Small
Cell Lung Cancer (NSCLC)
Advanced Non–Small Cell Lung Cancer (NSCLC)
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg/m2 and carboplatin AUC 6 mg•min/mL dosing bottles for advanced non–small cell lung cancer (NSCLC) - icon
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg/m2 and carboplatin AUC 6 mg•min/mL dosing bottles for advanced non–small cell lung cancer (NSCLC) - icon

ILLUSTRATIVE PURPOSES ONLY

  • Administer ABRAXANE on Days 1, 8, and 15 of each 21-day cycle
  • Administer carboplatin on Day 1 only of each 21-day cycle, beginning immediately after the completion of ABRAXANE administration
  • ABRAXANE is administered intravenously over 30 minutes
  • ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • Administer ABRAXANE on
    Days 1, 8, and 15 of each
    21-day cycle
  • Administer carboplatin on
    Day 1 only of each 21-day
    cycle, beginning immediately
    after the completion of
    ABRAXANE administration
  • ABRAXANE is administered
    intravenously over 30 minutes
  • ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL